595 related articles for article (PubMed ID: 27830456)
1. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
[TBL] [Abstract][Full Text] [Related]
2. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
3. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
4. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
5. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
[TBL] [Abstract][Full Text] [Related]
6. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
[TBL] [Abstract][Full Text] [Related]
7. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
[TBL] [Abstract][Full Text] [Related]
8. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
; Nathan DM; Lachin JM; Bebu I; Burch HB; Buse JB; Cherrington AL; Fortmann SP; Green JB; Kahn SE; Kirkman MS; Krause-Steinrauf H; Larkin ME; Phillips LS; Pop-Busui R; Steffes M; Tiktin M; Tripputi M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1075-1088. PubMed ID: 36129997
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
10. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Jørgensen PG; Jensen MT; Mensberg P; Storgaard H; Nyby S; Jensen JS; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Jul; 19(7):1040-1044. PubMed ID: 28188972
[TBL] [Abstract][Full Text] [Related]
11. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.
Liang B; Gu N
Cardiovasc Diabetol; 2020 Jul; 19(1):106. PubMed ID: 32631360
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
Ferrario MG; Lizán L; Montagnoli R; Ramírez de Arellano A
Prim Care Diabetes; 2016 Jun; 10(3):220-6. PubMed ID: 26546244
[TBL] [Abstract][Full Text] [Related]
15. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
16. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.
Usui R; Yabe D; Kuwata H; Murotani K; Kurose T; Seino Y
J Diabetes Complications; 2015; 29(8):1203-10. PubMed ID: 26279320
[TBL] [Abstract][Full Text] [Related]
18. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
[TBL] [Abstract][Full Text] [Related]
19. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J; Hyötyläinen T; Orešič M; Nyström T
Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
[TBL] [Abstract][Full Text] [Related]
20. [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?].
Lanthier L; Mutchmore A; Plourde MÉ; Cauchon M
Rev Med Interne; 2023 Jan; 44(1):48-49. PubMed ID: 36443201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
